Meta-analysis: rapid infliximab infusions are safe.

@article{Neef2013MetaanalysisRI,
  title={Meta-analysis: rapid infliximab infusions are safe.},
  author={Haley C. Neef and Meredith P Riebschleger and Jonathan Eric Adler},
  journal={Alimentary pharmacology & therapeutics},
  year={2013},
  volume={38 4},
  pages={
          365-76
        }
}
BACKGROUND Infliximab is typically administered intravenously via 2- to 3-h duration infusions. Infusions are time-consuming and costly. Shorter duration infusions are administered at some centres. Limited safety data are available on shorter duration infusions. AIM To determine risk of infusion reaction associated with standard 2- to 3-h infusions vs. rapid infusions in patients receiving infliximab therapy for inflammatory bowel disease (IBD), rheumatoid arthritis, spondylarthopathy and… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach

Y El Miedany, D. Palmer
  • Rheumatology (Oxford)
  • 2011

Similar Papers

Loading similar papers…